<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font17 { font-size : 17; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font29 { font-size : 29; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">the </span>
   <span class="font29">and </span>
   <span class="font17">for </span>
   <span class="font17">with </span>
   <span class="font16">[]. </span>
   <span class="font16">feline </span>
   <span class="font15">virus </span>
   <span class="font15">cats </span>
   <span class="font15">FIV </span>
   <span class="font14">immunodeficiency </span>
   <span class="font14">treatment </span>
   <span class="font14">are </span>
   <span class="font13">against </span>
   <span class="font13">that </span>
   <span class="font13">was </span>
   <span class="font13">FIV-infected </span>
   <span class="font13">but </span>
   <span class="font13">not </span>
   <span class="font12">{background </span>
   <span class="font12">antiviral </span>
   <span class="font12">been </span>
   <span class="font12">yes </span>
   <span class="font12">studies </span>
   <span class="font12">HIV </span>
   <span class="font12">clinical </span>
   <span class="font12">vitro </span>
   <span class="font12">[,]. </span>
   <span class="font12">which </span>
   <span class="font12">The </span>
   <span class="font12">active </span>
   <span class="font12">has </span>
   <span class="font12">viral </span>
   <span class="font12">infection </span>
   <span class="font12">margin </span>
   <span class="font12">replication </span>
   <span class="font12">can </span>
   <span class="font12">effects </span>
   <span class="font12">have </span>
   <span class="font12">reverse </span>
   <span class="font12">{border-style </span>
   <span class="font11">also </span>
   <span class="font11">human </span>
   <span class="font11">used </span>
   <span class="font11">px;} </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">DNA </span>
   <span class="font11">effect </span>
   <span class="font11">side </span>
   <span class="font11">some </span>
   <span class="font11">transcriptase </span>
   <span class="font11">efficacy </span>
   <span class="font11">oral </span>
   <span class="font11">vivo </span>
   <span class="font11">cats. </span>
   <span class="font11">drug </span>
   <span class="font11">inhibitors </span>
   <span class="font11">nucleoside </span>
   <span class="font11">Vet. </span>
   <span class="font11">compounds </span>
   <span class="font11">effective </span>
   <span class="font11">naturally </span>
   <span class="font11">other </span>
   <span class="font11">Inhibitors </span>
   <span class="font11">activity </span>
   <span class="font11">cell </span>
   <span class="font11">infected </span>
   <span class="font11">likely </span>
   <span class="font11">because </span>
   <span class="font11">drugs </span>
   <span class="font11">during </span>
   <span class="font11">from </span>
   <span class="font11">shown </span>
   <span class="font11">toxic </span>
   <span class="font11">treated </span>
   <span class="font11">zidovudine </span>
   <span class="font11">U/kg </span>
   <span class="font11">approved </span>
   <span class="font11">including </span>
   <span class="font11">many </span>
   <span class="font11">most </span>
   <span class="font11">ribavirin </span>
   <span class="font11">secondary </span>
   <span class="font11">this </span>
   <span class="font10">Feline </span>
   <span class="font10">administration </span>
   <span class="font10">after </span>
   <span class="font10">anti-HIV </span>
   <span class="font10">consecutive </span>
   <span class="font10">improvement </span>
   <span class="font10">proviral </span>
   <span class="font10">rFeIFN-ω </span>
   <span class="font10">site </span>
   <span class="font10">study </span>
   <span class="font10">therapy </span>
   <span class="font10">there </span>
   <span class="font10">type </span>
   <span class="font10">available </span>
   <span class="font10">cells </span>
   <span class="font10">days </span>
   <span class="font10">effective, </span>
   <span class="font10">enzyme </span>
   <span class="font10">group </span>
   <span class="font10">inhibitor </span>
   <span class="font10">interferon </span>
   <span class="font10">into </span>
   <span class="font10">leukemia </span>
   <span class="font10">one </span>
   <span class="font10">potent </span>
   <span class="font10">px; </span>
   <span class="font10">therefore </span>
   <span class="font10">two </span>
   <span class="font10">use </span>
   <span class="font10">{font-family </span>
   <span class="font10">Agents </span>
   <span class="font10">FIV, </span>
   <span class="font10">RNA </span>
   <span class="font10">Suramin </span>
   <span class="font10">There </span>
   <span class="font10">Virol. </span>
   <span class="font10">bind </span>
   <span class="font10">both </span>
   <span class="font10">cats, </span>
   <span class="font10">different </span>
   <span class="font10">dose </span>
   <span class="font10">experimental </span>
   <span class="font10">font-size </span>
   <span class="font10">inhibit </span>
   <span class="font10">inhibits </span>
   <span class="font10">possibly </span>
   <span class="font10">resistance </span>
   <span class="font10">results </span>
   <span class="font10">selective </span>
   <span class="font10">such </span>
   <span class="font10">than </span>
   <span class="font10">three </span>
   <span class="font10">through </span>
   <span class="font10">viruses </span>
   <span class="font10">were </span>
   <span class="font10">(e.g., </span>
   <span class="font10">.De </span>
   <span class="font10">Adefovir </span>
   <span class="font10">EBM </span>
   <span class="font10">HIV- </span>
   <span class="font10">However, </span>
   <span class="font10">Pharmacol. </span>
   <span class="font10">They </span>
   <span class="font10">Thus, </span>
   <span class="font10">Transcriptase </span>
   <span class="font10">[,,]. </span>
   <span class="font10">binding </span>
   <span class="font10">chain </span>
   <span class="font10">data </span>
   <span class="font10">did </span>
   <span class="font10">double; </span>
   <span class="font10">gene </span>
   <span class="font10">high </span>
   <span class="font10">immune </span>
   <span class="font10">inhibition </span>
   <span class="font10">nucleotide </span>
   <span class="font10">protease </span>
   <span class="font10">resistant </span>
   <span class="font10">severe </span>
   <span class="font10">study, </span>
   <span class="font10">virus-infected </span>
   <span class="font10">vitro, </span>
   <span class="font10">within </span>
   <span class="font10">CXCR </span>
   <span class="font10">Foscarnet </span>
   <span class="font10">Human </span>
   <span class="font10">IFN-α </span>
   <span class="font10">IFNs </span>
   <span class="font10">Immunol. </span>
   <span class="font10">Med. </span>
   <span class="font10">Nucleotide </span>
   <span class="font10">Res../ </span>
   <span class="font10">Reverse </span>
   <span class="font10">Ribavirin </span>
   <span class="font10">This </span>
   <span class="font10">U/cat </span>
   <span class="font10">adefovir </span>
   <span class="font10">administered </span>
   <span class="font10">anti-FIV </span>
   <span class="font10">antiretroviral </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">cellular </span>
   <span class="font10">chemokine </span>
   <span class="font10">combination </span>
   <span class="font10">common </span>
   <span class="font10">effects, </span>
   <span class="font10">field </span>
   <span class="font10">first </span>
   <span class="font10">ineffective </span>
   <span class="font10">infections </span>
   <span class="font10">integrase </span>
   <span class="font10">intracellular </span>
   <span class="font10">its </span>
   <span class="font10">lamivudine </span>
   <span class="font10">licensed </span>
   <span class="font10">might </span>
   <span class="font10">mutation </span>
   <span class="font10">natural </span>
   <span class="font10">new </span>
   <span class="font10">non-nucleoside </span>
   <span class="font10">only </span>
   <span class="font10">phosphate </span>
   <span class="font10">plerixafor </span>
   <span class="font10">receptor </span>
   <span class="font10">recombinant </span>
   <span class="font10">retroviral </span>
   <span class="font10">solid; </span>
   <span class="font10">synthesis </span>
   <span class="font10">these </span>
   <span class="font10">toxicity </span>
   <span class="font10">veterinary </span>
   <span class="font10">years </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(most </span>
   <span class="font10">Abacavir </span>
   <span class="font10">Acad. </span>
   <span class="font10">Chemother../AAC... </span>
   <span class="font10">Didanosine </span>
   <span class="font10">Interferons </span>
   <span class="font10">Intern. </span>
   <span class="font10">Lamivudine </span>
   <span class="font10">NARTIs </span>
   <span class="font10">NNRTIs </span>
   <span class="font10">Natl. </span>
   <span class="font10">Plerixafor </span>
   <span class="font10">Res. </span>
   <span class="font10">Sci. </span>
   <span class="font10">Stavudine </span>
   <span class="font10">Tenofovir </span>
   <span class="font10">USA./pnas... </span>
   <span class="font10">Zidovudine </span>
   <span class="font10">[,], </span>
   <span class="font10">acid </span>
   <span class="font10">acid, </span>
   <span class="font10">acyclic </span>
   <span class="font10">addition, </span>
   <span class="font10">agents </span>
   <span class="font10">alternative </span>
   <span class="font10">article </span>
   <span class="font10">associated </span>
   <span class="font10">blood </span>
   <span class="font10">bold </span>
   <span class="font10">compound. </span>
   <span class="font10">controlled </span>
   <span class="font10">courier; </span>
   <span class="font10">days) </span>
   <span class="font10">decrease </span>
   <span class="font10">development </span>
   <span class="font10">double-blinded </span>
   <span class="font10">em; </span>
   <span class="font10">every </span>
   <span class="font10">experimentally </span>
   <span class="font10">foscarnet </span>
   <span class="font10">grade </span>
   <span class="font10">had </span>
   <span class="font10">humans </span>
   <span class="font10">infection) </span>
   <span class="font10">interfere </span>
   <span class="font10">long </span>
   <span class="font10">low </span>
   <span class="font10">major </span>
   <span class="font10">marked </span>
   <span class="font10">necessary </span>
   <span class="font10">parenteral </span>
   <span class="font10">placebo </span>
   <span class="font10">placebo-controlled </span>
   <span class="font10">placebo-controlled, </span>
   <span class="font10">potential </span>
   <span class="font10">potentially </span>
   <span class="font10">prevent </span>
   <span class="font10">produced </span>
   <span class="font10">pt;} </span>
   <span class="font10">raltegravir </span>
   <span class="font10">recent </span>
   <span class="font10">receptors </span>
   <span class="font10">response </span>
   <span class="font10">retrovirus </span>
   <span class="font10">retroviruses </span>
   <span class="font10">review </span>
   <span class="font10">should </span>
   <span class="font10">showed </span>
   <span class="font10">significant </span>
   <span class="font10">signs </span>
   <span class="font10">similar </span>
   <span class="font10">target </span>
   <span class="font10">their </span>
   <span class="font10">various </span>
   <span class="font10">when </span>
   <span class="font10">without </span>
  </p>
 </body>
</html>
